| 1 |
17214606 | Metabolic drug interactions with newer antipsychotics: a comparative review. | 2007 Jan |
1 |
| 2 |
15821046 | Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. | 2005 Jul |
2 |
| 3 |
15570533 | [Risk of QTc prolongation due to combination of ziprasidone and quetiapine]. | 2004 Nov |
2 |
| 4 |
12665390 | Fatalities associated with therapeutic use and overdose of atypical antipsychotics. | 2003 |
1 |
| 5 |
12670127 | Interactions between the cytochrome P450 system and the second-generation antipsychotics. | 2003 Mar |
1 |
| 6 |
12826984 | Ziprasidone metabolism, aldehyde oxidase, and clinical implications. | 2003 Jun |
3 |
| 7 |
11978164 | Ziprasidone: the fifth atypical antipsychotic. | 2002 May |
2 |
| 8 |
12186270 | New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. | 2002 Jul |
1 |
| 9 |
10771452 | Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. | 2000 |
5 |
| 10 |
10771457 | The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. | 2000 |
1 |